Responses to measles immunization in children infected with human immunodeficiency virus

Area of Science:

• Pediatric Infectious Diseases
• Immunology
• Public Health

Background:

• Measles immunization is a critical public health intervention.
• Children with human immunodeficiency virus (HIV) infection may have altered immune responses.
• Optimal timing for measles vaccination in immunocompromised children requires further investigation.

Purpose of the Study:

• To compare the immunogenicity of measles vaccination in children with and without HIV infection.
• To evaluate the impact of vaccination timing (6-12 months vs. after 12 months) on measles antibody responses in these groups.
• To inform vaccination guidelines for children with HIV.

Main Methods:

• Retrospective cohort study comparing antibody responses to measles immunization.
• Participants categorized based on HIV status and age at primary immunization (6-12 months vs. >12 months).
• Serological assessment of measles-specific antibodies post-vaccination.

Main Results:

• No significant difference in measles antibody response was observed when immunization was given between 6 and 12 months, regardless of HIV status.
• Children with HIV infection demonstrated a significantly poorer antibody response to measles immunization administered after 12 months compared to their HIV-uninfected counterparts.
• These findings highlight a potential window of reduced vaccine efficacy in HIV-infected children if vaccination is delayed.

Conclusions:

• Early measles immunization (between 6-12 months) is effective in children with and without HIV infection.
• Delayed measles immunization (after 12 months) is associated with suboptimal immune response in children with HIV infection.
• Consideration should be given to administering primary measles immunization earlier in children diagnosed with HIV.